MiniMed MMED

-4.0%vs Day 1

Spinoff of Medtronic (MDT) · IPO Carve-Out · Spun Mar 6, 2026

BUYExpected return (11/13/2026): +38% Gain to loss: 5.8 : 1

The No. 2 insulin-pump maker, 70% international, independent of Medtronic since October 15, 2026 with no debt. Priced for an even chance of the worst case: cases $39.90 / $25.11 / $12.27, weighted 20/55/25 $24.86, +32%. The margin path from 9.9% in Q1 to the 16% guide, Medicare bidding from 2028 and the Fit patch pump (summer 2027) decide it. BUY, target $25.

Current Stats

Post-Spinoff Performance

Timeline
Spinoff dateMarch 6, 2026 · Nasdaq
Days since spinoff253 days
StructureIPO Carve-Out
ParentMedtronic (MDT)
Day-1 reaction
Day 1 open$19.05
Day 1 return (open→close)-2.9%
Day 1 price (close)$18.49 reported $19.05 (open)
Day 1 range$18.25 – $20.48 +12.2% spread
Day 1 low held?Breached after 1 session to -41.6% below
Price levels
Post-spin low (closing)$10.80 on May 15, 2026 · 70 days post-spin
Current price (Nov 13, 2026)$17.99
Returns
Return vs Day 1 (close)-2.7%
— range by day 1 entry theoretical bounds-12.2%  to  -1.4%
Return vs post-spin low+66.6%
First-quarter return (≈90d)-24.0%
Versus benchmarks
S&P 500 over same window+13.0%
Shares & ownership
Shares outstanding Jul 31, 2026281,205,548
Diluted average shares the EPS denominator281,000,000
Free float281,265,526 100% of shares outstanding
Held by institutions27% insiders 0.6%
Share count trend Apr 2025 → Jul 2026+0.1% broadly flat
Volume & liquidity
Traded per day 20-session median$134M
Normal volume baseline909,150 shares · now 8.15x
Day 1 volume9.7x normal · first week 3.5x
Decayhalf in 2 sessions · normal by 8

Computed from split-adjusted closing prices. Returns are total return — (end price + dividends received − start price) ÷ start price — with no reinvestment assumed.

Price History

Closing price, split-adjusted, with volume below. No dividends have been paid, so price return and total return are the same. Source: Yahoo Finance. Data through Nov 14, 2026.

Raw daily price & volume data
DateOpenHighLowCloseVolumeFloatTurnoverMarket capDividendSplit
2026-11-13$17.92$18.15$17.65$17.995,376,900281,265,5261.91%$5.06B——
2026-11-12$18.23$18.30$17.62$17.883,271,500281,265,5261.16%$5.03B——
2026-11-11$17.46$18.66$17.25$18.255,553,700281,265,5261.97%$5.13B——
2026-11-10$17.53$17.71$17.25$17.364,453,300281,265,5261.58%$4.88B——
2026-11-09$16.98$17.89$16.78$17.886,196,600281,265,5262.20%$5.03B——
2026-11-06$18.25$18.25$16.66$16.717,479,400281,265,5262.66%$4.70B——
2026-11-05$19.63$19.63$17.75$18.1610,043,400281,265,5263.57%$5.11B——
2026-11-04$19.33$19.93$19.11$19.2911,782,700281,265,5264.19%$5.42B——
2026-11-03$18.77$19.05$18.51$18.855,713,700281,265,5262.03%$5.30B——
2026-11-02$18.38$19.03$18.20$18.906,752,900281,265,5262.40%$5.31B——
2026-10-30$19.48$19.48$18.04$18.288,134,000281,265,5262.89%$5.14B——
2026-10-29$19.01$19.55$19.01$19.257,334,500281,265,5262.61%$5.41B——
2026-10-28$18.87$19.32$18.60$19.2110,305,100281,265,5263.66%$5.40B——
2026-10-27$18.66$18.99$18.22$18.938,001,100281,265,5262.85%$5.32B——
2026-10-26$18.29$18.69$18.07$18.665,289,700281,265,5261.88%$5.25B——
2026-10-23$18.47$18.47$17.94$18.344,801,600281,265,5261.71%$5.16B——
2026-10-22$17.69$18.35$17.56$18.299,782,000281,265,5263.48%$5.14B——
2026-10-21$17.31$18.11$17.29$17.8010,345,100281,265,5263.68%$5.01B——
2026-10-20$18.10$18.13$17.36$17.4910,860,700281,265,5263.86%$4.92B——
2026-10-19$17.52$18.11$17.24$17.7917,460,000281,265,5266.21%$5.00B——
2026-10-16$17.70$18.00$17.38$17.4921,451,400281,265,5267.63%$4.92B——
2026-10-15$16.65$18.08$16.60$18.0027,731,700281,279,5949.86%$5.06B——
2026-10-14$18.17$18.40$16.56$16.8167,620,800281,279,59424.05%$4.73B——
2026-10-13$19.14$19.35$18.37$18.4033,606,900281,279,59411.95%$5.17B——
2026-10-12$18.87$19.49$18.46$18.8038,550,60028,466,98613.71%$5.29B——
2026-10-09$19.79$20.15$19.47$19.7118,395,90028,466,9866.54%$5.54B——
2026-10-08$19.08$19.83$18.94$19.8023,336,10028,466,9868.30%$5.57B——
2026-10-07$19.57$19.64$19.03$19.119,619,30028,466,9863.42%$5.37B——
2026-10-06$19.79$20.00$19.40$19.6415,506,30028,466,9865.51%$5.52B——
2026-10-05$19.69$20.17$19.03$20.1615,347,60028,466,9865.46%$5.67B——
2026-10-02$19.53$19.98$19.29$19.704,695,10028,466,9861.67%$5.54B——
2026-10-01$19.51$19.64$19.25$19.603,933,10028,466,9861.40%$5.51B——
2026-09-30$20.07$20.12$19.44$19.474,024,50028,466,9861.43%$5.48B——
2026-09-29$20.31$20.37$19.73$20.043,344,60028,466,9861.19%$5.64B——
2026-09-28$19.97$20.51$19.80$20.493,729,70028,466,9861.33%$5.76B——
2026-09-25$20.75$20.75$19.71$19.982,554,40028,466,9860.91%$5.62B——
2026-09-24$20.69$21.03$20.29$20.443,413,50028,466,9861.21%$5.75B——
2026-09-23$21.17$21.26$20.37$20.542,845,30028,466,9861.01%$5.78B——
2026-09-22$21.68$21.69$20.99$21.202,803,90028,466,9861.00%$5.96B——
2026-09-21$22.14$22.30$21.09$21.122,331,70028,466,9860.83%$5.94B——
2026-09-18$22.10$22.17$21.74$21.792,881,50028,466,9861.02%$6.13B——
2026-09-17$22.57$22.68$21.74$22.032,730,50028,466,9860.97%$6.19B——
2026-09-16$22.14$23.36$22.09$22.404,068,10028,466,9861.45%$6.30B——
2026-09-15$22.52$22.52$21.70$22.012,127,10028,466,9860.76%$6.19B——
2026-09-14$21.50$22.73$21.27$21.974,386,50028,466,9861.56%$6.18B——
2026-09-11$23.03$23.74$22.28$22.501,423,60028,466,9860.51%$6.33B——
2026-09-10$22.54$23.17$22.10$22.441,651,10028,466,9860.59%$6.31B——
2026-09-09$23.22$23.31$22.51$22.761,587,70028,466,9860.56%$6.40B——
2026-09-08$23.16$23.44$22.74$23.321,052,10028,466,9860.37%$6.56B——
2026-09-04$23.84$23.90$23.17$23.291,719,30028,011,1990.61%$6.55B——
2026-09-03$23.88$24.16$23.19$23.844,268,10027,960,7141.52%$6.70B——
2026-09-02$22.78$24.43$22.62$23.764,491,60027,960,7141.60%$6.68B——
2026-09-01$20.40$22.74$19.65$22.426,075,20027,960,7142.16%$6.30B——
2026-08-31$19.97$20.37$19.72$20.262,482,10027,960,7140.88%$5.70B——
2026-08-28$19.77$20.25$19.60$20.101,329,30027,960,7140.47%$5.65B——
2026-08-27$19.69$19.84$19.11$19.511,306,40027,960,7140.46%$5.49B——
2026-08-26$18.86$19.56$18.85$19.491,244,60027,960,7140.44%$5.48B——
2026-08-25$19.95$19.95$18.85$18.921,102,40027,960,7140.39%$5.32B——
2026-08-24$20.45$20.68$19.63$19.94910,60027,960,7140.32%$5.61B——
2026-08-21$20.34$20.74$19.86$20.451,119,10027,960,7140.40%$5.75B——
2026-08-20$20.07$20.84$19.79$20.181,424,50027,960,7140.51%$5.67B——
2026-08-19$19.61$20.31$19.37$20.221,619,40027,960,7140.58%$5.69B——
2026-08-18$19.55$20.27$19.19$19.361,501,60027,960,7140.53%$5.44B——
2026-08-17$20.14$20.25$19.19$19.531,516,40027,960,7140.54%$5.49B——
2026-08-14$20.07$20.42$19.75$20.151,069,20027,449,5800.38%$5.67B——
2026-08-13$20.65$20.88$20.02$20.021,092,100—0.39%$5.63B——
2026-08-12$19.60$20.72$19.40$20.701,311,600—0.47%$5.82B——
2026-08-11$19.68$19.95$19.10$19.78779,600—0.28%$5.56B——
2026-08-10$19.72$19.93$19.33$19.501,076,500—0.38%$5.48B——
2026-08-07$18.37$19.76$18.37$19.601,629,900—0.58%$5.51B——
2026-08-06$18.56$18.95$18.32$18.42499,800—0.18%$5.18B——
2026-08-05$18.87$19.01$18.19$18.561,043,500—0.37%$5.22B——
2026-08-04$19.00$19.25$18.75$18.991,045,000—0.37%$5.34B——
2026-08-03$18.48$19.19$18.38$19.10921,700—0.33%$5.37B——
2026-07-31$18.15$18.24$17.66$18.05613,400—0.22%$5.08B——
2026-07-30$18.38$18.66$18.10$18.15821,400—0.29%$5.10B——
2026-07-29$18.12$18.67$17.71$18.401,636,000—0.58%$5.17B——
2026-07-28$17.91$18.36$17.61$17.641,757,500—0.63%$4.95B——
2026-07-27$17.00$17.76$16.97$17.671,915,700—0.68%$4.96B——
2026-07-24$16.28$16.97$16.25$16.831,102,700—0.39%$4.73B——
2026-07-23$16.51$16.60$15.96$16.33749,900—0.27%$4.59B——
2026-07-22$16.69$17.47$16.00$16.33969,000—0.35%$4.59B——
2026-07-21$16.85$17.51$16.68$16.701,125,500—0.40%$4.69B——
2026-07-20$16.93$17.33$16.80$16.921,158,000—0.41%$4.75B——
2026-07-17$15.71$17.15$15.67$16.932,402,000—0.86%$4.75B——
2026-07-16$15.43$16.41$15.40$15.881,252,500—0.45%$4.46B——
2026-07-15$15.18$15.84$15.03$15.42939,400—0.33%$4.33B——
2026-07-14$16.19$16.27$14.78$15.04964,400—0.34%$4.22B——
2026-07-13$15.49$16.28$15.17$16.101,411,700—0.50%$4.52B——
2026-07-10$15.05$15.37$14.70$15.29833,200—0.30%$4.29B——
2026-07-09$15.04$15.40$14.79$15.05480,000—0.17%$4.23B——
2026-07-08$15.29$15.51$14.76$15.021,055,700—0.38%$4.22B——
2026-07-07$15.21$15.48$15.01$15.37524,500—0.19%$4.32B——
2026-07-06$15.59$15.85$15.22$15.291,031,200—0.37%$4.29B——
2026-07-02$15.34$15.76$15.18$15.59447,200—0.16%$4.38B——
2026-07-01$14.87$15.74$14.87$15.19859,700—0.31%$4.27B——
2026-06-30$14.90$15.55$14.26$14.95847,100—0.30%$4.20B——
2026-06-29$14.17$15.13$14.08$14.881,339,500—0.48%$4.18B——
2026-06-26$14.22$14.67$13.73$14.246,306,900—2.25%$4.00B——
2026-06-25$14.25$14.76$13.94$14.22653,100—0.23%$3.99B——
2026-06-24$13.97$14.98$13.95$14.131,111,700—0.40%$3.97B——
2026-06-23$14.14$14.49$13.73$13.74537,600—0.19%$3.86B——
2026-06-22$14.61$14.96$14.12$14.22631,500—0.22%$3.99B——
2026-06-18$14.39$14.96$14.17$14.772,855,000—1.02%$4.15B——
2026-06-17$15.02$15.37$14.11$14.17561,400—0.20%$3.98B——
2026-06-16$15.04$15.36$14.70$14.70460,500—0.16%$4.13B——
2026-06-15$15.17$15.52$14.87$15.001,020,000—0.36%$4.21B——
2026-06-12$15.37$15.68$15.00$15.16963,100—0.34%$4.26B——
2026-06-11$14.43$15.54$14.24$15.471,413,700—0.50%$4.34B——
2026-06-10$15.18$15.49$14.66$14.71748,600—0.27%$4.13B——
2026-06-09$14.89$15.69$14.74$15.12798,900—0.28%$4.25B——
2026-06-08$14.31$15.00$14.22$14.88742,200—0.26%$4.18B——
2026-06-05$14.23$14.64$14.01$14.23457,600—0.16%$4.00B——
2026-06-04$14.26$15.23$14.03$14.061,263,000—0.45%$3.95B——
2026-06-03$12.72$14.70$12.62$14.262,965,600—1.06%$4.00B——
2026-06-02$12.00$12.45$11.46$12.301,062,600—0.38%$3.45B——
2026-06-01$12.04$12.55$11.83$12.001,086,600—0.39%$3.37B——
2026-05-29$11.85$12.08$11.29$12.04574,100—0.20%$3.38B——
2026-05-28$10.80$11.70$10.72$11.51569,900—0.20%$3.23B——
2026-05-27$11.29$11.57$10.80$10.80730,700—0.26%$3.03B——
2026-05-26$11.90$11.90$11.17$11.18516,200—0.18%$3.14B——
2026-05-22$11.71$12.19$11.59$11.87696,300—0.25%$3.33B——
2026-05-21$11.63$11.94$11.34$11.72617,900—0.22%$3.29B——
2026-05-20$10.89$11.68$10.75$11.63811,100—0.29%$3.27B——
2026-05-19$10.86$11.35$10.69$10.89634,800—0.23%$3.06B——
2026-05-18$10.80$11.47$10.75$10.88631,600—0.22%$3.06B——
2026-05-15$11.00$11.24$10.65$10.80578,000—0.21%$3.03B——
2026-05-14$11.29$11.39$10.92$11.08471,800—0.17%$3.11B——
2026-05-13$11.67$12.02$11.02$11.181,116,400—0.40%$3.14B——
2026-05-12$11.31$12.11$11.19$11.891,054,900—0.38%$3.34B——
2026-05-11$11.60$11.88$11.10$11.16579,500—0.21%$3.13B——
2026-05-08$11.79$12.08$11.25$11.57538,400—0.19%$3.25B——
2026-05-07$11.73$12.15$11.68$11.73394,400—0.14%$3.29B——
2026-05-06$11.68$12.09$11.45$11.79439,200—0.16%$3.31B——
2026-05-05$11.91$12.17$11.52$11.68452,500—0.16%$3.28B——
2026-05-04$12.07$12.41$11.80$11.87542,100—0.19%$3.33B——
2026-05-01$12.35$12.74$12.07$12.11580,800—0.21%$3.40B——
2026-04-30$12.22$12.68$12.05$12.34718,900—0.26%$3.47B——
2026-04-29$12.93$13.04$12.01$12.02659,700—0.23%$3.38B——
2026-04-28$12.92$13.39$12.69$12.94642,800—0.23%$3.63B——
2026-04-27$13.24$13.46$12.77$12.92531,900—0.19%$3.63B——
2026-04-24$13.59$13.59$12.80$13.20670,200—0.24%$3.71B——
2026-04-23$13.20$13.69$12.89$13.63907,700—0.32%$3.83B——
2026-04-22$13.41$13.72$13.07$13.19431,700—0.15%$3.70B——
2026-04-21$13.80$13.82$13.09$13.20850,200—0.30%$3.71B——
2026-04-20$14.35$15.24$13.57$13.81566,700—0.20%$3.88B——
2026-04-17$14.14$15.06$14.01$14.44816,600—0.29%$4.05B——
2026-04-16$15.13$15.22$13.84$14.021,671,100—0.60%$3.94B——
2026-04-15$15.05$15.80$15.05$15.221,065,900—0.38%$4.27B——
2026-04-14$14.42$15.48$14.42$15.211,080,400—0.38%$4.27B——
2026-04-13$13.90$14.43$13.75$14.391,407,400—0.50%$4.04B——
2026-04-10$14.01$14.70$13.89$13.92663,600—0.24%$3.91B——
2026-04-09$13.42$14.09$13.17$13.801,265,900—0.45%$3.88B——
2026-04-08$13.55$13.75$13.05$13.56692,600—0.25%$3.81B——
2026-04-07$13.15$13.54$12.80$13.201,123,000—0.40%$3.71B——
2026-04-06$14.10$14.42$13.18$13.23971,900—0.35%$3.72B——
2026-04-02$14.27$14.97$13.52$14.01725,600—0.26%$3.93B——
2026-04-01$15.08$15.08$14.13$14.48992,000—0.35%$4.07B——
2026-03-31$14.73$15.40$14.53$14.921,550,100—0.55%$4.19B——
2026-03-30$14.30$15.05$14.10$14.35888,600—0.32%$4.03B——
2026-03-27$15.22$15.55$14.37$14.47725,600—0.26%$4.06B——
2026-03-26$16.11$16.38$15.05$15.27867,600—0.31%$4.29B——
2026-03-25$16.40$16.94$16.01$16.01667,300—0.24%$4.50B——
2026-03-24$17.01$17.20$16.01$16.31476,300—0.17%$4.58B——
2026-03-23$16.89$17.70$16.55$17.10522,700—0.19%$4.80B——
2026-03-20$17.11$17.86$16.26$16.57693,400—0.25%$4.65B——
2026-03-19$16.75$17.24$16.46$17.11399,200—0.14%$4.80B——
2026-03-18$16.81$17.55$16.64$16.791,043,600—0.37%$4.71B——
2026-03-17$16.02$16.89$15.97$16.831,035,600—0.37%$4.73B——
2026-03-16$15.90$16.24$15.55$15.96794,000—0.28%$4.48B——
2026-03-13$16.57$17.16$15.18$15.762,126,400—0.76%$4.43B——
2026-03-12$18.35$18.38$16.51$16.532,359,200—0.84%$4.64B——
2026-03-11$18.26$18.39$17.85$18.051,518,800—0.54%$5.07B——
2026-03-10$18.03$18.69$17.98$18.331,318,000—0.47%$5.15B——
2026-03-09$18.50$19.05$17.94$18.001,945,300—0.69%$5.05B——
2026-03-06$19.05$20.48$18.25$18.498,823,200—3.14%$5.19B——

Close is split-adjusted to current shares. It is not dividend-adjusted: dividends are listed separately, so total return is (end price + dividends received − start price) ÷ start price, checkable by hand. Volume is as-traded.

Momentum: MACD and RSI

Top: MACD (navy) and its signal line (gold); bars show the gap between them, teal when MACD is above.
Bottom: RSI over 14 days; above 70 is usually read as overbought and below 30 as oversold.
The lines start late because MACD needs 26 trading days of prices and RSI 14 before the first value.
The colored strip under the charts shows the state label day by day; hover for the state and the reason.
Both measure momentum in the price and say nothing about value. Hover for each day's arithmetic.
Source: closing prices from this site's daily price archive (Yahoo Finance), not adjusted for dividends. Data through Nov 14, 2026.

How these are calculated

Short Selling

Bars: shares sold short each day in trades reported to FINRA (off-exchange trades, roughly half of all volume).
Line: the short share of that volume, averaged over 20 sessions.
Gold points: short interest, the shares sold short and not yet bought back, reported twice a month, also shown as a percentage of the free float and of shares outstanding.
Daily short volume includes market makers' routine hedging, so a change in the share is more informative than its level. Hover for each day's figures.
Sources: FINRA; float from this site's daily share records; shares outstanding from the company's latest quarterly filing. Data through Nov 13, 2026.

Post-Spin Analysis — November 2, 2026: the first full analysis — BUY, target $25

Written against the November 2, 2026 close of $18.90. Sources: the FY2026 10-K (year to April 24, 2026), the first-quarter FY2027 10-Q and results release (September 2026), the IPO prospectus (March 6, 2026), the exchange-offer registration statement (September 14, 2026), the change-in-control 8-K (October 16, 2026), Medtronic’s final exchange results, peers’ filings, FDA establishment registrations, FINRA short interest, fund holdings filings, and analyst actions as collected by MarketBeat. Peer prices are Yahoo closes; MiniMed’s prices and volumes are from this site’s own archive. The monthly reports carried MiniMed as NOT RATED while Medtronic held 90%; this is the first valuation the site has published.

The one-line version

MiniMed is the second-largest insulin-pump maker, independent of Medtronic since October 15, 2026, with no debt. It sold $3.10 billion in FY2026, 70% outside the United States, and has about 659,000 pump users. As a Medtronic segment it earned an adjusted EBITDA margin of only 6.5%; management guides about 16% for FY2027, and the first quarter delivered 9.9%.

Three cases are worth $39.90, $25.11 and $12.27 a share (a ten-year cash-flow valuation at 9%). Weighted 20% best, 55% base and 25% worst, they are worth $24.86, an expected return of +31.5%, with $4.60 of probability-weighted gain for each dollar of loss. The price implies nothing on the best case and an even chance of the worst.

What decides it is the margin. Each point of long-run margin is worth about $1.70 a share, and the path from 9.9% to 16% depends on Medtronic’s transition charges ($95 million in the first quarter) falling away. Medicare’s competitive bidding from January 2028 and the MiniMed Fit patch pump (summer 2027) are the two events after that. A sale is ruled out until about October 15, 2028 by the tax agreement with Medtronic.

What the business actually is

  • Insulin pumps and the supplies they use. The MiniMed 780G, an automated insulin-delivery system that adjusts doses from a glucose sensor, and since June 2026 the smaller MiniMed Flex. Pumps were $546 million of FY2026 revenue; infusion sets and reservoirs, which every pump user buys every few days, $956 million.
  • Continuous glucose monitors (CGM). MiniMed’s own Simplera sensors and, since 2026, the Instinct sensor that Abbott makes for it under a seven-year agreement. CGM was $1,553 million, the largest line, and grew 18%.
  • Recurring revenue is 82% of the total: sensors, sets, software and service. A pump is sold about once every four years; its user buys supplies every month.
  • 70% of revenue is outside the United States, about 39% from the European Union. MiniMed has the most pump users in Germany, Italy, Spain, Benelux, the Nordics and Israel, and is second in the United Kingdom, France and Australia. In the United States it lost share after an FDA warning letter in December 2021 (lifted in April 2023); U.S. revenue grew 2% in FY2026 against 21% abroad.
  • New products: MiniMed Go, a connected insulin pen (launched in Europe in February 2026 and the United States in May 2026); MiniMed Fit, a patch pump submitted to the FDA in August 2026 for a U.S. launch in summer 2027; the Vivera fully closed-loop algorithm (U.S. launch expected in the second half of 2027); and an Abbott glucose-ketone sensor exclusive to MiniMed, expected in 2027.
Revenue, $ millionsFY2024FY2025FY2026Q1 FY2026Q1 FY2027
Pumps540541546119144
Consumables777854956229261
CGM1,1171,3131,553360431
Other34646157
Total2,4692,7153,102723843
Organic growth8.6%11.5%8.0%7.8%15.8%
United States833903917212240
International1,6361,8122,185511603

Fiscal years end in late April. Q1 FY2027 had 14 weeks, against 13; the extra week added 4–6 points of growth.

Management Team

  • Que Dallara, chief executive. She has run Medtronic Diabetes since May 2022, through the lifting of the warning letter in 2023 and the separation. Before that she was chief executive of Honeywell Connected Enterprise (2018–22), with earlier roles at TE Connectivity, Microsoft and McKinsey. FY2026 pay was $8.4 million.
  • Chad Spooner, chief financial officer since July 2025; before that chief financial officer of Société BIC (2020–25) and earlier at GE.
  • The board fell from 11 to 8 when four Medtronic directors resigned on October 15, 2026. Amy Bricker, formerly president of Express Scripts, joined; David Endicott, Alcon’s chief executive, joined in June 2026. Kevin Lofton chairs it. One remaining director was Medtronic’s head of strategy at the time of the August 2026 proxy.
  • Directors and officers owned less than 1% in August 2026. Since the IPO they have made no open-market purchases or sales; their Forms 4 show only grants and shares withheld for tax. Performance shares granted at the IPO vest only if the stock closed at $32.05 or more on the day Medtronic left, which it did not.

The financial record — three years as a Medtronic segment

$ millionsFY2024FY2025FY2026Q1 FY2026Q1 FY2027
Revenue2,4692,7153,102723843
Gross margin58.2%56.3%54.2%56.6%55.1%
Research and development437436448125115
Selling, general and administrative1,0571,0801,183283312
Operating income (loss)(69)(146)(190)(13)5
Net income (loss) to the company(112)(213)(333)(19)0
Adjusted EBITDA (company’s)1472532025083
Adjusted EBITDA margin6.0%9.3%6.5%6.9%9.8%
Operating cash flow less capital spending(107)(53)(420)(194)(90)
  • The reported losses carry Medtronic’s allocations and one-time charges. FY2026 includes a $157 million charge for the minimum royalty owed to Blackstone, which funded the Flex pump’s development, $118 million to end a manufacturing contract, and $36 million of separation costs. Medtronic allocated $298–344 million a year of corporate costs to the segment.
  • The company’s adjusted EBITDA excludes stock compensation ($46 million in FY2026) as well as separation, restructuring and litigation costs. The valuation below charges stock compensation as a cost and the separation cash as it is paid.
  • The cash flow is not yet a standalone one. Medtronic still collects most international revenue as MiniMed’s agent until each customer contract transfers, so money owed by Medtronic rose to $602 million at July 31, 2026. As the contracts move, that balance comes back as cash.
  • The gross margin fell four points in two years, from 58.2% to 54.2%. About 2.7 points of FY2026’s figure is a one-time $84 million write-off on ending a manufacturing contract; on the company’s adjusted basis the fall is 1.7 points, from 59.3% to 57.6%, as CGM, which earns less than pumps and sets, grew faster and sensor prices fell, especially outside the United States. The 10-Q says the newer Simplera sensor earns less than the older Guardian and the Instinct sensors.

The separation: what Medtronic took and what MiniMed carries

StepDateTerms
IPOMarch 6, 202628.0 million shares at $20.00, below the $25–28 range; $538 million net; $229 million paid to Medtronic to repay an intercompany note; Medtronic kept 252.8 million shares (90%)
Exchange offerSeptember 14 – October 9, 2026$107.53 of MiniMed stock for each $100 of Medtronic stock, capped at 4.5939 MiniMed shares per Medtronic share; the cap applied
ResultOctober 15, 2026297.5 million Medtronic shares tendered for 55.0 million accepted (18.29%); Medtronic exchanged all 252,813,348 MiniMed shares and owns none

What MiniMed carries after it:

  • Transition services from Medtronic: about 160 agreements, 17 exited so far, most of the rest in calendar 2027. Fees are cost-based, rise 3% a year, and carry a 25–50% surcharge if extended past their terms. They cost $95 million in the first quarter of FY2027, part of “other operating expense”. Medtronic also supplies sensor wafers and analog chips for two years under a manufacturing agreement.
  • The tax matters agreement keeps the split-off tax-free for Medtronic. Until about October 15, 2028 MiniMed cannot be party to a change of 35% or more of its shares, cannot sell more than 20% of its assets outside the ordinary course, and can buy back shares only within narrow limits. Its indemnity to Medtronic is uncapped.
  • Litigation: the Series 600 pump retainer-ring cases stay with MiniMed, uncapped and uninsured: 28 suits for 109 people in August 2026 and about 2,000 more claimants threatened; $20 million is accrued.
  • The Blackstone royalty: a $157 million minimum on Flex over its first two years on the market, then a royalty until a multiple of the funding is repaid. MiniMed Fit is funded the same way, with a $162 million minimum to be charged when it launches.
  • A single infusion-set supplier, Convatec’s Unomedical, received an FDA warning letter on January 8, 2026.

How the money moves

Where each $100 of revenue went, first quarter of FY2027 (Q1 FY2027, 14 weeks to July 31, 2026, as reported). The quarter consumed about $11 of each $100, about $90 million, but almost all of that was money owed by Medtronic, which still collects most international revenue as MiniMed’s agent until the customer contracts transfer. Without the growth of that balance, about $2 of each $100 was left (an estimate). The company guides the year’s adjusted EBITDA margin to about 16%, against 9.8% in this quarter, which needs the Medtronic service charges and separation costs to fall away. Source: the Q1 FY2027 10-Q and results release; per-$100 figures are calculations.

Who pays MiniMed, and whom MiniMed pays:

  • Patients through insurers and national health systems. In the United States about 72% ships directly to patients and 28% through distributors, mostly through medical-equipment suppliers; only a small share goes through pharmacies, which is where rivals Insulet and, since March 2026, Tandem sell. About 69% of U.S. direct patients have commercial insurance. Outside the United States, tenders and national reimbursement set prices; Italy claws back part of device spending above a cap.
  • Medtronic, for transition services ($95 million a quarter), wafers and chips, and a share of the Juncos plant it leases for up to ten years. It also still collects international revenue and pays it over.
  • Abbott, for the Instinct sensors, at a formula price, exclusive both ways for certain systems, until about 2033.
  • Blackstone, a royalty on Flex and, from 2027, Fit sales.

The debt: none, and what stands in its place

ItemAmountTerms
Revolving credit facility$500 million, undrawnCitibank agent; matures March 2031; SOFR plus 1.25–1.625%; secured; covenants: secured net leverage at most 3.50 times, interest cover at least 2.50 times
Cash, July 31, 2026+ ~$207 million
Due from Medtronic, less due to Medtronic+ ~$424 millionRevenue Medtronic collected as agent; comes back as contracts transfer
Blackstone minimum royalty− ~$157 millionOver Flex’s first two years on the market
Operating leases− ~$59 million
Net cash used in the valuation= ~$415 millionAbout $1.45 a share

There is no rated debt and no credit rating. The covenants allow buybacks and dividends of $100 million or 25% of EBITDA a year, and without limit below three times net leverage, but the tax agreement limits buybacks until October 2028.

Where MiniMed is

Two own plants, Northridge (California; 508,000 sq ft, buildings owned on leased land) and Juncos (Puerto Rico; 252,000 sq ft, owned), which makes products behind most of the revenue, with Medtronic leasing part of it. Distribution runs through Louisville (Kentucky) and Heerlen (Netherlands) and 26 smaller sites. About 8,000 employees. 70% of FY2026 revenue came from outside the United States, about 39% from the EU. The Instinct sensor is Abbott’s (Kilkenny, Witney, Alameda); infusion sets come from a single supplier, Convatec, in Mexico and Denmark. The sales companies are shown at their registered addresses. Click a point for details. Map data © OpenStreetMap contributors. Source: the FY2026 10-K (Properties, manufacturing and suppliers), FDA establishment registrations, MiniMed’s legal-entity list (May 2026) and news; points placed with OpenStreetMap, at the city or park centre where no address is public. As of November 2, 2026.

The supply chain runs mostly through the Americas: own manufacturing at Northridge and Juncos; the MiniMed Flex pump made by Jabil in Tijuana; infusion sets by Convatec in Reynosa (its parent received an FDA warning letter on January 8, 2026) and inserters by SMC in Costa Rica; Instinct sensor kits assembled by Flex in Aguascalientes; sterilization in California. Medtronic supplies sensor wafers and analog chips under a two-year agreement; the Tempe, Arizona site is inferred, not named. Click a point for details. Map data © OpenStreetMap contributors. Source: the FY2026 10-K (Properties, manufacturing and suppliers), FDA establishment registrations, MiniMed’s legal-entity list (May 2026) and news; points placed with OpenStreetMap, at the city or park centre where no address is public. As of November 2, 2026.

  • Two plants of its own. Northridge, California (headquarters, manufacturing and most of the research; 508,000 square feet) and Juncos, Puerto Rico (252,000 square feet), which makes the sensors, pumps and reservoirs behind most of the revenue. The tax agreement requires MiniMed to keep a minimum workforce at Juncos for about two years.
  • The rest is made by others. Jabil in Tijuana makes the Flex pump; Convatec makes the infusion sets in Reynosa, Mexico, and Osted, Denmark; SMC in Costa Rica makes the inserters; Abbott makes the Instinct sensor in Ireland, the United Kingdom and California; Flex assembles sensor kits in Mexico and China.
  • About 8,000 employees. Distribution runs through Louisville, Kentucky, and Heerlen, the Netherlands. Almost all of the $711 million of plant and equipment, $673 million, is in the United States and Puerto Rico.
  • Sites without a public address are placed approximately, at the city or park centre. The Medtronic site that supplies wafers is inferred to be Tempe, Arizona; the filings do not name it.

The scenarios and the asymmetry

The cases. Revenue starts from FY2026 as reported and FY2027 at the guidance (about 10.5% organic growth, about 1.5 points of currency): $3.47 billion. After that, growth and the adjusted EBITDA margin are set by case. Stock compensation (1.4% of revenue) and depreciation (5.0%) come off the company’s adjusted EBITDA; tax is 20% to FY2028 and 21% after, because U.S. losses shelter part of the profit; capital spending is 6.5% of revenue in FY2027, 6.0% in FY2028 and 5.5% after (it averaged 6.8% in FY2024–26); separation and restructuring cash is $140 million in FY2027 and $60 million in FY2028. Each case is a ten-year cash-flow valuation at 9% with 3% terminal growth, plus the $415 million above, on 287.1 million shares including unvested awards. There is no earlier published value to reproduce; the model returns FY2027 adjusted EBITDA of $556 million at the guidance.

CaseWhat it assumesFY2028 revenue / marginValuevs $18.90
BestFit and Vivera win back U.S. share; growth above 10% into FY2030; the margin reaches about Insulet’s, 25%, by FY2031 as the transition charges end$3.86 billion / 19%$39.90+111%
BaseThe FY2027 guidance met; FY2028 flat in earnings as Medicare bidding, the end of transition services and the Fit launch arrive together (as analysts’ estimates have it); growth fading to 4%; the margin rising to 20% by FY2031$3.77 billion / 16.5%$25.11+33%
WorstShare lost to patch pumps and CGM-integrated rivals; the FY2027 guidance missed (14.5%); Medicare bid rates cut prices from 2028 and set commercial benchmarks; the margin stays near 14%$3.58 billion / 13.5%$12.27−35%

Growth, margins and the 9% discount rate are judgements. All values are estimates from the model.

Base case, $ millionsFY2027FY2028FY2029FY2030FY2031
Revenue3,4733,7684,0704,3554,616
Adjusted EBITDA margin16.0%16.5%18.0%19.0%20.0%
Adjusted EBITDA556622733827923
Free cash flow (after separation costs)73195328389452
Earnings a share, on cash tax (estimate)$0.93$1.06$1.30$1.51$1.73

The model’s earnings a share use the 20–21% cash tax; analysts’ estimates ($0.70 for FY2027 and $0.69 for FY2028) use a higher book tax rate, which carries a valuation allowance against U.S. losses.

Checks on the cases. The values sit inside the range a multiple of sales gives: the base case is 1.8 times FY2028 revenue against 1.3–1.5 times for MiniMed and Tandem today, and the best case 2.9 times against Insulet’s 2.9 times next-year sales. Free cash flow reaches 10% of revenue only in FY2031 in the base case; Insulet’s is about 15%. The terminal value is 64% of the base case’s enterprise value, so the discount rate matters (below).

Stress tests, one change at a time on the base case (estimates):

ChangeValuevs $18.90
A margin of 23% by FY2031 instead of 20%$30.45+61%
Discount rate 8% instead of 9%$30.25+60%
Growth 2 points a year higher in FY2028–32$27.16+44%
Terminal growth 3.5% instead of 3%$26.57+41%
Terminal growth 2.5%$23.88+26%
Growth 2 points a year lower in FY2028–32$23.21+23%
Medicare bidding: U.S. prices about 5% lower from FY2028, all off the margin$22.20+17%
Discount rate 10%$21.45+13%
Capital spending 7% of revenue throughout$21.45+13%
The margin stuck at 17% from FY2029$19.82+5%

Discount rate against terminal growth (base case value a share; rows are the discount rate, columns the long-run growth rate after FY2036; the base case uses 9% and 3%):

Discount rate ↓ · terminal growth →Growth 2.0%Growth 2.5%Growth 3.0%Growth 3.5%
Discount rate 8.0%$26.79$28.36$30.25$32.56
Discount rate 8.5%$24.65$25.93$27.45$29.27
Discount rate 9.0%$22.82$23.88$25.11$26.57
Discount rate 9.5%$21.24$22.13$23.14$24.33
Discount rate 10.0%$19.86$20.61$21.45$22.43

FY2031 margin against the discount rate (base case value a share; rows are the adjusted EBITDA margin reached in FY2031 and held after, columns the discount rate; the base case uses 20% and 9%):

FY2031 margin ↓ · discount rate →Discount rate 8%Discount rate 9%Discount rate 10%
Margin 17.0%$23.84$19.91$17.12
Margin 18.5%$27.09$22.56$19.33
Margin 20.0%$30.25$25.11$21.45
Margin 21.5%$33.37$27.63$23.54
Margin 23.0%$36.49$30.14$25.62

The margin decides the value. Every grid cell is above $18.90 except a 17% margin at 10%. A margin that stops at 17% leaves the base case 5% above the price, and one that stops at 16.5% gives exactly the price, $18.90.

Three weightings, and what the price implies. The standard set, 25 / 50 / 25, and the stress set, 10 / 40 / 50, are the same for every company; the best guess drives the target and the two chips at the top of the page.

Weights, best / base / worstValueExpected returnGain to loss
Standard: 25 / 50 / 25$25.60+35.5%5.0 to 1
Best guess: 20 / 55 / 25$24.86+31.5%4.6 to 1
Stress: 10 / 40 / 50$20.17+6.7%1.4 to 1
What the price implies: 0 / 52 / 48$18.900%1.0 to 1

The weights are a judgement. All values are estimates from the model.

Why the best guess:

  • The best case takes 20%, below the standard 25%. It needs the margin to more than double from the first quarter’s 9.9%, and the 16% guidance already needs about 18% in the rest of FY2027. Fit launches with capacity for about 20,000 patients, years behind Insulet’s Omnipod, and one analyst’s channel checks (Jefferies, October 2026) point to MiniMed holding its share, not gaining it.
  • The worst case takes 25%, the standard weight. All three earlier companies separated by an IPO followed by an exchange offer (Envista, Kenvue, Elanco) trailed medical-device stocks by 9–27 points in their first year. Medicare’s competitive bidding starts on January 1, 2028, and its rates are expected to become benchmarks for commercial insurers. The sole infusion-set supplier is under an FDA warning letter, and the retainer-ring litigation is uncapped.
  • The base case takes 55%. U.S. new-pump sales grew more than 20% in the first quarter, the guidance was raised in September 2026, 40% of U.S. new starts are type 2 patients, and the main patch-pump rival, Insulet, cut its 2026 U.S. growth guidance on type 2 retention and issued two device corrections.
  • Evidence that would move the weights: the second-quarter adjusted EBITDA margin (about 18% is needed for the year), the number of transition agreements exited, U.S. new-pump growth, Fit’s FDA clearance, and Medicare’s bid rates (best case up if the margin is on track and Fit is cleared early; worst case up on a margin below 15%, a guidance cut or a supply problem at Convatec).

What the price implies. At a 55% base weight the price is below every mix of the base and best cases, so the best case is set to zero and the price solves

base weight × $25.11 + (100% − base weight) × $12.27 = $18.90

for a base weight of ($18.90 − $12.27) ÷ ($25.11 − $12.27) = 52%, leaving 48% on the worst case.

The asymmetry on the best guess:

MeasureAt $18.90What it means
Expected return (header chip)+31.5%The probability-weighted value, $24.86, against the price
Gain to loss (header chip)4.6 to 1+$7.62 of probability-weighted gain against −$1.66 of loss
Expected base-case gain ÷ expected worst-case loss2.1 to 1+$3.42 against −$1.66
Best-case gain ÷ worst-case loss3.2 to 1+$21.00 against −$6.63
Base-case gain ÷ worst-case loss0.94 to 1+$6.21 against −$6.63

How the measures are calculated. Gain = case value − price; loss = price − case value. Weights are the best guess: 20% best, 55% base, 25% worst.

MeasureFormulaAt $18.90
Expected return(20% × best + 55% × base + 25% × worst) ÷ price − 1($7.98 + $13.81 + $3.07) ÷ $18.90 − 1 = +31.5%
Gain to loss(20% × best gain + 55% × base gain) ÷ (25% × worst loss)($4.20 + $3.42) ÷ $1.66 = 4.6
Expected base ÷ expected worst(55% × base gain) ÷ (25% × worst loss)$3.42 ÷ $1.66 = 2.1
Best ÷ worstbest gain ÷ worst loss$21.00 ÷ $6.63 = 3.2
Base ÷ worstbase gain ÷ worst loss$6.21 ÷ $6.63 = 0.94
Price-implied base weight, best at zero(price − worst) ÷ (base − worst)$6.63 ÷ $12.84 = 52%

The header chips are green at +25% or more and 3 to 1 or better, blue at +10–25% and 2–3 to 1, orange at 0–10% and 1–2 to 1, and red below zero and below 1 to 1. On the best guess, expected return is green below $19.89, blue up to $22.60 and orange up to $24.86; gain to loss is green below $20.67, blue up to $22.34 and orange up to $24.86. Both are green at $18.90.

Who has been trading MiniMed

Closing prices rebased to March 6 = 100. Baskets are equal-weighted: diabetes devices (Insulet, Tandem, Dexcom); Medtronic, the former parent; medical devices and the S&P 500 through their ETFs (IHI, SPY). Cumulative turnover is measured against all 281.3 million shares, so it understates turnover of the 28 million-share float before October 15, 2026. Source: Yahoo Finance closes.

Since the IPO the stock has done better than its peers, but not the market. From the first close of $18.49 on March 6, 2026 to October 30, 2026 it fell 1%, against −8.5% for diabetes devices (Insulet, Tandem, Dexcom), −4% for medical devices and +12% for the S&P 500. It fell 42% to $10.80 by May 15, 2026 with the diabetes group (Insulet −38%, Tandem −39% over the same weeks); no MiniMed news explains the fall. It rose 16% on the fourth-quarter results (June 3, 2026) and 17% over two days on the first-quarter results and raised guidance (September 1–2, 2026), to a closing high of $23.84 on September 3, 2026.

Daily volume (bars) and cumulative volume as a share of the 281.35 million shares outstanding (line). Gold bars mark days with a notable event; hover over one to see what happened. Source: this site's daily price archive (Yahoo Finance), through Oct 30, 2026.

The exchange offer moved more shares than the whole IPO float. Before October 15, 2026 only the 28.0 million IPO shares traded, and average volume was about 1 million shares a day. Arbitrageurs bought Medtronic, tendered it and sold MiniMed short against the shares they expected: short interest rose from 8.1 million shares at the end of August 2026 to 20.7 million on October 15, 2026, about 74% of the old float. Volume reached 67.6 million shares on October 14, 2026, when the stock closed at the low of the offer, $16.81, the day the final results confirmed 252.8 million shares would be delivered the next morning. It recovered over the next two weeks, to $19.25 on October 29, 2026, as index funds raised MiniMed’s weight to its full share count.

Index membership, now and next:

IndexNowEvidenceNext
Russell 2000Yes, since June 26, 2026iShares Russell 2000 ETF holdingsWeight raised to the full share count around October 15–20, 2026 (probable); stays in the Russell 2000 at the December 11, 2026 reconstitution (about $5.3 billion, below the $5.7 billion breakpoint)
S&P Total Market and CompletionYesVanguard Extended Market and other holdingsWeight raised with the exchange (probable)
S&P Healthcare Equipment Select Industry (XHE)Yes, since September 2026Equal-weighted—
S&P 500, MidCap 400, SmallCap 600NoNot eligible: S&P requires positive GAAP earnings over the last four quarters and in the latestNot before mid-2027
CRSP (Vanguard Total Stock Market, Small-Cap)No at June 30, 2026Vanguard’s holdings filingsProbable addition at the December 2026 rebalance
MSCI USA Small CapNoNo MSCI-tracking fund holds itProbable addition at the November 2026 review, announced November 11, 2026, effective at the November 30, 2026 close

The weight changes and additions marked probable are inferences from the rules and fund holdings, not announcements.

The likely additions are buying, not selling. CRSP and MSCI funds together would need an estimated 20–28 million shares (an estimate from the funds’ typical holdings), five to nine days of volume at 3–5 million shares a day, between the November 11, 2026 announcement and mid-December 2026. Index buying usually moves the price between the announcement and the effective date.

Holders. Susquehanna’s group filed for 21.9 million shares (7.8%) at October 15, 2026, including options on 0.9 million: shares received by tendering Medtronic, most likely held against other positions. MFS Mid Cap Value held 4.3 million shares at June 30, 2026, the largest fund holding in the filings so far. Third-quarter 13F filings, due November 16, 2026, will show who kept the shares Medtronic’s holders received. The company has bought back no stock.

Short interest and volatility

ReportSettledShort% float% outst.Days to cover
First after the spinMar 13, 20261.34M4.9%0.5%1.0
Three months earlierJul 15, 20266.35M23.1%2.3%7.5
LatestOct 30, 20269.81M3.5%3.5%1.0

The latest share of float is higher than 0 of the 15 earlier reports since the spin. Short interest in shares, with its share of the float and of shares outstanding. FINRA settlement dates; figures are published about eight business days later. Days to cover is short interest divided by average daily volume, as reported by FINRA. Float and shares outstanding on or before each date, from this site's daily share records and the company's filings.

Short interest was 20.7 million shares on October 15, 2026, 7.4% of the shares outstanding after the exchange and about one day of that month’s heavy volume. Most of it was the arbitrage against the offer, which closes as the delivered shares cover it; the October 31, 2026 figure, due about November 10, 2026, should show how much remains.

Volatility, annualizedLast 20 sessionsLast 60 sessionsSince the spin
To November 13, 202658%55%57%

At the last 60 sessions' volatility, one standard deviation over a month is about ±17%, or $15.34 to $21.10 from the $17.99 close; about two months in three end inside that range if volatility holds. The median daily move since the spin is 2.3%.

Results dayReleasedClose beforeClose afterMoveTimes a median day
June 3, 2026Before the open$12.30$14.26+15.9%6.9×
September 1, 2026Before the open$20.26$22.42+10.7%4.6×

Average move on a results day: 13.3% either way, against a median day's 2.3%. Next results: November 24, 2026. The move is measured from the close before the release to the close of the first session after it.

Results days have moved the stock 11–16%: +15.9% on June 3, 2026 and +10.7% on September 1, 2026 (then a further +6.0%), both released before the open.

What this most resembles

CompanySeparatedHowFirst-year returnAgainst medical devices
Envista (from Danaher)December 2019IPO, then exchange offer+14.3%−8.9 points
Kenvue (from Johnson & Johnson)August 2023IPO, then exchange offer−4.1%−16.2 points
Elanco (from Eli Lilly)March 2019IPO, then exchange offer−19.9%−27.3 points
Embecta (from BD; diabetes injection devices)April 2022Spinoff−6.4%+5.7 points
Solventum (from 3M)April 2024Spinoff+10.5%+6.4 points
GE HealthCare (from GE)January 2023Spinoff+26.7%+26.9 points
Alcon (from Novartis)April 2019Spinoff−9.8%−15.3 points

Price returns over twelve months from the first full separation, against the iShares medical-devices ETF (IHI).

The closest structural matches did worst. The three that went public first and then left through an exchange offer all trailed their sector in the first year, by 9–27 points; across all seven the median is about 9 points behind. Embecta, also a diabetes-device business separated from a large parent, is the cautionary case over a longer period: it has lost 72% since its first trade, as falling prices for a commodity product met the cost of standing alone. MiniMed’s growth (about 10%) and its pipeline are what separate it from Embecta’s flat sales.

In depth: competitive dynamics

  • The market. MiniMed puts its market at more than $19 billion and growing above 10% a year to 2030 (Seagrove Partners, March 2026, in the exchange-offer filing). About 45% of U.S. type 1 patients use a pump, against fewer than 15% of insulin-requiring type 2 patients; outside the United States the type 1 share is above 25%.
  • Pumps and supplies (about $6 billion among listed makers, an estimate from their revenue): Insulet about 55% (Omnipod, a tubeless patch), MiniMed about 25%, Tandem about 18%, Beta Bionics about 2%. Insulet grew 23.5% in the June 2026 quarter at a 24.9% adjusted EBITDA margin; Tandem guides 2026 revenue of $1.065–1.085 billion at a 5–6% margin.
  • CGM (about $15.5 billion): Abbott about $8.7 billion (including meters), Dexcom about $5.2 billion at a 32% adjusted EBITDA margin, MiniMed about $1.55 billion. MiniMed’s sensors work mainly with its own pumps.
  • The patch pumps are coming. Beta Bionics’ Mint was cleared in September 2026 for a 2027 launch, Tandem has submitted a tubeless Mobi, and Sequel’s twiist launched nationally in March 2026. MiniMed’s Fit arrives in summer 2027.
  • The channel is moving to pharmacies. Pharmacy benefit coverage lets a patient start without a large upfront payment; Tandem’s pharmacy sales reached 10% of U.S. sales in their first full quarter. MiniMed sells mostly through equipment suppliers and is building its own pharmacy (licensed in about 40 states).
  • Medicare competitive bidding covers pumps and CGM from January 1, 2028, with about ten winning suppliers and a move to 60-month pump rental; diabetes groups asked Congress for a delay on October 14, 2026.
  • GLP-1 drugs may reduce how many type 2 patients need intensive insulin. Insulet’s guidance cut in August 2026 cited type 2 retention; MiniMed says it sees no “alarming” attrition.

In depth: valuation against peers

CompanyEV / sales, next yearEV / EBITDAGrowthAdjusted EBITDA or operating margin
MiniMed (at $18.28, October 30, 2026)1.34x9.1x FY2027 guidance~10.5% guided16% guided
Insulet2.91x~13.5x21%~25% adj. EBITDA
Dexcom5.25x18.1x12%32% adj. EBITDA
Tandem1.34x~27x6%5–6% adj. EBITDA
Embecta1.52x~4.9x−5%24% operating
Beta Bionics3.66xn/m25%losses

At October 30, 2026 closes; consensus estimates from Yahoo/LSEG, retrieved November 2, 2026. Multiples marked ~ are estimates from guided margins. Saved with sources in the analysis folder.

On peers’ multiples MiniMed’s value depends on which company it is compared with. At Tandem’s 1.34 times next year’s sales it is worth today’s price; at the 2 times FY2027 sales BofA used when it began coverage in March 2026, about $26 (an estimate); at Insulet’s 2.9 times, about $39, close to the best case. The base case, $25.11, is 1.8 times FY2028 revenue and about 11 times its FY2028 adjusted EBITDA, between Insulet and Embecta. Diabetes-device deals since 2018 (LifeScan in 2018 and Owen Mumford’s pen needles in 2026) were done at 1.4 times sales, for slower businesses; no scaled pump or CGM maker has changed hands in that time.

In depth: is MiniMed an acquisition target?

Not before about October 15, 2028. A sale of 35% or more before then would breach the tax matters agreement, and MiniMed would owe Medtronic the tax, without a cap, even if it did not arrange the deal. Its charter adds a staggered board and no shareholder right to call meetings. After 2028 the natural buyers are the companies whose sensors or patients it shares: Abbott, which already supplies its sensor exclusively, and Roche, Dexcom or a medical-device group without a pump. No approach has been reported. A sale is an option for 2029, not part of the value above.

What would change this view

  • Upward: a second-quarter adjusted EBITDA margin of 17% or more; transition agreements exited faster than planned; Fit cleared before summer 2027; U.S. new-pump growth above 15%; Medicare bid rates that spare the incumbents; the index additions bringing new holders.
  • Downward: a margin below 15% or a guidance cut; a supply interruption at Convatec; a recall; a large litigation charge; Medicare rates that cut U.S. prices by more than 10%; Insulet’s or Tandem’s patch pumps taking MiniMed’s type 2 starts.

Investment Scorecard

DimensionWeightScoreRationale
Financial Profile25%2.5No debt, $415 million of net cash and receivables, and 82% recurring revenue. Marked down for a 6.5% FY2026 margin, an adjusted gross margin down 1.7 points in two years, cash flow that has been negative as a segment, and a 16% guidance not yet shown
Competitive Position25%3.0Second in pumps worldwide and first in much of Europe, with the most-satisfied U.S. users since 2024 and an exclusive Abbott sensor. Held at 3.0 because it lost U.S. share, has no patch pump until 2027, and depends on equipment suppliers while rivals move to pharmacies
Strategic Rationale20%3.5A complete separation that leaves no debt and an undistracted management. Held at 3.5 for the $229 million taken by Medtronic and about 160 transition agreements still running
Management & Governance20%3.0A chief executive who has run the business since 2022 and brought it through the warning letter; an independent board since October 2026. Insiders own less than 1% and have bought no shares; the chief financial officer is new to the business
Acquisition Potential10%2.0Natural buyers exist, but the tax agreement rules out a sale until about October 2028
Weighted Score2.88
Investment GradeBAverage Opportunity

The grade moves from B- in the monthly reports to B (2.88). The filings show a business with no debt and a clean exit by Medtronic, which the reports could not score while the exchange was pending; the margin record keeps it from B+.

The grade is about the business; the rating is about the price. A B business at 1.3 times next year’s sales, priced for an even chance of its worst case, is a BUY.

What it means for the rating

NOT RATED → BUY, target $25. The target is the best-guess value, $24.86. At $18.90 the expected return is +31.5% and the gain to loss 4.6 to 1, both inside the BUY band. It is BUY rather than ACCUMULATE because the price already assumes the margin stalls near 16.5% and gives no weight to the best case, so the margin path management has guided to is not in the price. It is not a larger position because the value rests on a margin that has not yet been reported, 64% of the base case is terminal value, and the price is $1 below the BUY edge.

ActionLevelReason
BuyBelow about $19.89Both chips green: expected return above 25% and gain to loss above 3 to 1
Accumulate$19.89–22.60Expected return 10–25%
Hold$22.60–27.62Expected return −10% to +10%
Trim$27.62–33.15Expected return −10% to −25%
SellAbove about $33.15Expected return below −25%
Move toward HOLDA second-quarter margin below 15%, a guidance cut, or a Convatec supply problem
Raise the targetA margin of 17% or more, transition agreements exited faster, Fit cleared early

What the second-quarter FY2027 results (about early December 2026) must show:

ItemWhy it mattersBase case needs
Adjusted EBITDA margin (9.8% in the first quarter)The year’s 16% needs about 18% from here15% or more, and the 16% guidance kept
Medtronic transition charges ($95 million in the first quarter) and agreements exited (17 so far)The margin path is mostly these costs endingFalling
Organic growth (15.8% with the extra week)The base case uses the 10.5% guidanceLow double digits without the extra week
U.S. new pumps (up more than 20%) and FlexU.S. share is the best case’s first conditionGrowth above 10%
The Medtronic receivable ($602 million)It should turn into cash as contracts transferLower
Fit’s FDA status and Medicare’s bidding timetableThe two events of 2027–28No delay to Fit